Fig. 2From: Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)Dose vs. adalimumab concentration. Red: ADA-positive patients. Green: frequency every 7 days. Blue: frequency every 14 daysBack to article page